Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma.

Lim, H. Y.; Lee, J.; Chang, H.; Kim, J. S.; Choi, H. J.; Lee, M. A.; Jang, J.; Jeung, H.; Kang, J. H.; Lee, H. W.; Shin, D.; Jang, H. J.; Sun, J.; Park, S. H.; Park, J. O.; Park, Y.; Kang, W. K.

doi:10.1200/jco.2011.29.15_suppl.lba4032

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this trial, EGFR mutation status was not evaluated, so it is unclear whether the responders correlated with mutational status. There is an ongoing, randomized phase III trial of gemcitabine and oxaliplatin in combination with erlotinib or placebo [32]. At the American Society of Clinical Oncology (ASCO) 2011 meeting, preliminary data from this trial were presented, indicating an improvement in PFS with the addition of erlotinib (5.8 vs. 4.2 months) in 285 patients.…”

Section: Epidermal Growth Factor Receptor/erbb1mentioning

confidence: 99%

Targeted therapy for biliary tract cancers

Faris

Zhu

2012

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

Biliary tract cancers (BTCs) are a heterogeneous group of malignancies, with a historically poor prognosis as a whole. Until recently, the development of effective therapeutics was hampered by the relatively low incidence, heterogeneity in patients and tumors, and correspondingly poor clinical trial enrollments. With the publication of the landmark phase III ABC-02 trial demonstrating the superiority of gemcitabine and cisplatin combination chemotherapy, the landscape changed for the development of new agents. Despite this progress, there are currently no approved targeted agents for BTC. This review will focus on recent developments in targeted therapeutics, directed against several key signaling pathways in BTC, including epidermal growth factor receptor, angiogenesis, and the mitogen-activated protein kinase pathway. Data from recent phase I and II trials will be discussed, along with a preview of upcoming trials involving targeted therapies.

show abstract

Section: Epidermal Growth Factor Receptor/erbb1mentioning

confidence: 99%

Targeted therapy for biliary tract cancers

Faris

Zhu

2012

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

show abstract

“…-Aucune donnée ne valide encore un agent ciblé seul ou en association à la chimiothérapie, tant en première ligne qu'au-delà. [20]. L'objectif principal (survie sans progression) n'a pas été atteint (p = 0,0796) dans la population globale de l'essai (n = 268), mais l'a été dans le sous-groupe des patients atteints de cholangiocarcinome (n = 180) (5,9 vs 3,0 mois, p = 0,0495).…”

Section: Take Home Messagesunclassified

Traitement systémique des cancers biliaires avancés : présent et futur

Williet¹,

Boige²,

Ducreux³

et al. 2012

Cancérodig.

View full text Add to dashboard Cite

Deux essais randomisés de phase III récents ont démontré que les combinaisons gemcitabine-platine (schémas GEMOX et GEMCIS) étaient supérieures en termes de survie globale aux meilleurs soins de support et à la gemcitabine seule, respectivement, faisant de ces deux schémas les options thérapeutiques de choix en première ligne de traitement des patients atteints de cancers biliaires avancés. Si aucune donnée ne permet de définir actuellement de standard au-delà de la première ligne, un schéma à base de fluoropyrimidine peut être proposé sur la foi d'une revue systématique de plus de 100 essais de chimiothérapie. L'inhibition ciblée d'altérations moléculaires oncogéniques tumorales d'intérêt, comme l'activation de la voie EGFR ou de MEK, seule ou en association à la chimiothérapie, a permis d'obtenir des premiers résultats encourageants.

show abstract

Molecular Targets in Biliary Carcinogenesis and Implications for Therapy

Oyasiji

Zhang²,

Kuvshinoff³

et al. 2015

The Oncologist

View full text Add to dashboard Cite

Biliary tract cancers (BTCs) encompass a group of invasive carcinomas, including cholangiocarcinoma (intrahepatic, perihilar, or extrahepatic), and gallbladder carcinoma. Approximately 90% of patients present with advanced, unresectable disease and have a poor prognosis. The latest recommendation is to treat advanced or metastatic disease with gemcitabine and cisplatin, although chemotherapy has recorded modest survival benefits.Comprehension of the molecular basis of biliary carcinogenesis has resulted in experimental trials of targeted therapies in BTCs, with promising results. This review addresses the emerging role of targeted therapy in the treatment of BTCs. Findings from preclinical studies were reviewed and correlated with the outcomes of clinical trials that were undertaken to translate the laboratory discoveries. The Oncologist 2015;20:742-751

show abstract

Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma.

Cited by 3 publications

References 0 publications

Targeted therapy for biliary tract cancers

Targeted therapy for biliary tract cancers

Traitement systémique des cancers biliaires avancés : présent et futur

Molecular Targets in Biliary Carcinogenesis and Implications for Therapy

Contact Info

Product

Resources

About